Recurrence: all 3,523 studies
Page 27 of 36. Open to participants first (870), then studies with results posted, then the rest; newest registration first within each.
- Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsWithdrawnNCT02420938Phase 2
- The Clinical Relevance of Immune Cells and CTC in HNSCC PatientsStatus unknownNCT02420600
- Optimal Dose Finding Study ABT-199 and Ibrutinib in MCLCompletedNCT02419560Phase 1
- A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.CompletedNCT02417285Phase 1
- The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade GliomaTerminatedNCT02414165Phase 2/3
- Sustained Viral Response in Chronic Hepatitis B Patients Who Achieved HBeAg Seroncongversion After Interferon TherapyStatus unknownNCT02412592
- SBRT for Extra-cranial Oligorecurrent TumorStatus unknownNCT02410187Phase 2
- Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT02406222Phase 2
- Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by EnterobacteriaceaeCompletedNCT02400268Phase 3
- Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution & Oncologic OutcomeCompletedNCT02399059Phase 3
- Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After HepatectomyStatus unknownNCT02399033Phase 4
- Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL PatientsActive, not recruitingNCT02390869Phase 3
- Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsWithdrawnNCT02389543Phase 1/2
- A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TRStatus unknownNCT02387879
- Dose EScalation Induction of EvERolimusCompletedNCT02387099Phase 2
- Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD)Active, not recruitingNCT02386670Not applicable
- The Predictive Value of CT-PET in Esophageal CancerCompletedNCT02385604
- Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated BoostActive, not recruitingNCT02384733Not applicable
- HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIACompletedNCT02379520Phase 1
- Left Atrial Geometry and Outcomes After Atrial Fibrillation AblationCompletedNCT02373982
- A Neuromuscular Exercise Program for Patients With Anterior Shoulder InstabilityCompletedNCT02371928Not applicable
- Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion ProteinCompletedNCT02364479Phase 4
- Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell LymphomaTerminatedNCT02356458Phase 1/2
- Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access StudyApproved for marketingNCT02355054
- Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck CancerCompletedNCT02350712Phase 1
- Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Phase 2
- A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian CancerCompletedNCT02344095Phase 1
- Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot StudyCompletedNCT02342392Phase 2/3
- Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular CancerActive, not recruitingNCT02341989Phase 3
- Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib TreatmentCompletedNCT02341781
- Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple MyelomaCompletedNCT02332850Phase 1
- Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic OsteomalaciaStatus unknownNCT02331966
- A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First RelapseCompletedNCT02330991Phase 2
- Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in RemissionCompletedNCT02324439Phase 1
- Combination Therapy Prevents the Relapse of RAStatus unknownNCT02320630Not applicable
- Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)CompletedNCT02315326Phase 1/2
- Length of the Proximal Resection Margin for Siewert-II/Siewert-III TumorsStatus unknownNCT02313688Not applicable
- Safety and PK Study of CC-90003 in Relapsed/Refractory Solid TumorsTerminatedNCT02313012Phase 1
- Study of Ibrutinib in Relapsed and Refractory T-cell LymphomaCompletedNCT02309580Phase 1
- Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal LoadStatus unknownNCT02308319Phase 4
- Glutamate Probes in Adolescent DepressionCompletedNCT02307617
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory NeuroblastomaActive, not recruitingNCT02298348Phase 1
- Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 MutationsTerminatedNCT02298166Phase 3
- Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 CarfilzomibTerminatedNCT02294357Phase 2
- Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA GenesActive, not recruitingNCT02286687Phase 2
- Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal EsophagusTerminatedNCT02283359Phase 1
- Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung AdenocarcinomaStatus unknownNCT02281708Phase 3
- Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma PatientsStatus unknownNCT02280993Phase 1
- Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005CompletedNCT02271412Phase 1
- Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic ImpairmentWithdrawnNCT02269579Phase 2
- Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell LymphomaTerminatedNCT02269085Phase 1
- Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCTStatus unknownNCT02267915Phase 2
- A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDSTerminatedNCT02267863Phase 1
- Phase I, Dose Escalation Study of DecitabineCompletedNCT02264873Phase 1
- OSCA - Olaparib Standard of CAre StudyCompletedNCT02262273
- Advanced Diagnostic Management of Suspected Recurrent Ipsilateral DVT With MRDTICompletedNCT02262052Not applicable
- Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.TerminatedNCT02247258Phase 2
- Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL AmyloidosisCompletedNCT02245867Phase 1
- Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT02244489Phase 1
- A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)CompletedNCT02244125Phase 2
- Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol RelapseCompletedNCT02242955Not applicable
- Biologic Versus Synthetic Mesh for Treatment of Paraesophageal HerniaStatus unknownNCT02242526Phase 4
- A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)TerminatedNCT02235740Phase 1
- Plegridy Observational ProgramCompletedNCT02230969
- Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid TumorsCompletedNCT02225002Phase 1
- A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological MalignanciesTerminatedNCT02223598Phase 1
- A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid TumorsCompletedNCT02221960Phase 1
- Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT02215629Phase 1
- Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersCompletedNCT02210858Phase 1/2
- Cisplatin Plus One-Day 24-hour Infusion of High-Dose 5-Fluorouracil for Stage IVB, Recurrent or Metastatic Carcinoma of the Uterine CervixCompletedNCT02207660
- Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)CompletedNCT02206503Phase 2
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsCompletedNCT02206425Phase 1/2
- Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDSWithdrawnNCT02204020Phase 2
- Pazopanib Vs. Pazopanib Plus GemcitabineActive, not recruitingNCT02203760Phase 2
- Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the BladderActive, not recruitingNCT02202772Phase 1/2
- Reducing Residual Depressive Symptoms With Web-based Mindful Mood BalanceCompletedNCT02190968Not applicable
- Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple MyelomaCompletedNCT02189343Phase 1
- Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast CancerStatus unknownNCT02188693
- Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial CancerStatus unknownNCT02188550Phase 2
- Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALLNo longer availableNCT02187354
- Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02187133Phase 1
- Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCCStatus unknownNCT02187081Not applicable
- Comparison of Tension Free Primary Closure, Karydaks and Limberg Flap MethodsCompletedNCT02186964Not applicable
- Interferon α for the Therapy of Minimal Residual DiseaseStatus unknownNCT02185261Not applicable
- Point in Time of Radiotherapy for Patients With Biochemical Recurrent Prostate CarcinomaStatus unknownNCT02181192Not applicable
- Magnetic Resonance Imaging of Mesh Position After Ventral Hernia RepairCompletedNCT02177214
- Response Monitoring Trial in Patients With Suspected Recurrence of GlioblastomaTerminatedNCT02176720Phase 1
- Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT02176213Phase 2
- Clinical Benefits of Additional Complex Fractionated Atrial Electrogram Targeted Catheter Ablation for Longstanding Persistent Atrial FibrillationCompletedNCT02175043Not applicable
- Post-Treatment Surveillance in Breast Cancer: Bringing CER to the AllianceCompletedNCT02171078
- A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)TerminatedNCT02166658Phase 2
- A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.CompletedNCT02164955
- Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)CompletedNCT02163720
- Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant NeuroblastomaTerminatedNCT02163356Phase 1
- The Efficacy of Brief Motivational Interviewing for Trauma Patients Related to Alcohol or Other Abuse Drugs.Status unknownNCT02159391Not applicable
- BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic CancerCompletedNCT02155088Phase 1
- Impact of Continuous Defocused CO2 Laser Vaporisation on the Histological Malignant Transformation of Erosive Oral Lichen Planus in PatientsCompletedNCT02154607Not applicable
- Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)Active, not recruitingNCT02152254Phase 2
- A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary CancerActive, not recruitingNCT02151084Phase 2
- An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.Status unknownNCT02145312Phase 2